SHERIDAN, WYOMING – May 6, 2025 – Boston Scientific Corporation (NYSE: BSX) has reported strong financial results for the first quarter of 2025, driven by sustained product demand, successful execution of its innovation strategy, and solid geographic performance. The company posted net sales of $4.663 billion, reflecting a 20.9% year-over-year increase on a reported basis, exceeding its own guidance range and affirming its leadership position in the global medical device sector.
Double-Digit Revenue Growth Across Segments and Regions
Boston Scientific achieved broad-based momentum across its business units and global markets:
- MedSurg segment delivered 11.7% reported growth (12.8% operational, 5.3% organic).
- Cardiovascular segment saw standout performance with 26.2% reported growth (27.6% operational, 25.6% organic).
Regional growth highlights included:
- United States: 31.1% reported and operational growth, underscoring strong domestic demand.
- EMEA: 5.5% reported growth, 7.9% operational.
- Asia-Pacific: 8.2% reported, 10.6% operational.
- Latin America and Canada: 4.4% reported, 14.1% operational.
- Emerging Markets: 6.5% reported, 9.8% operational.
These results point to effective market penetration, resilient sales strategies, and increased demand for high-impact therapies across diverse geographies.
Financial Outperformance Reinforces Strategic Direction
The company’s adjusted earnings per share (EPS) reached $0.75, up from $0.56 a year ago and above the high end of its guidance range. GAAP EPS stood at $0.45, aligning with forecast expectations.
“We delivered an exceptional quarter to start the year, reflecting the effectiveness of our highly engaged global team and the strength of our product portfolio,” said Mike Mahoney, chairman and chief executive officer, Boston Scientific. “We remain well-positioned for the future as we continue to focus on meaningful innovation, clinical science and the execution of our category leadership strategy to drive differentiated growth and performance for the long-term.”
Clinical Innovation and Strategic Trials Advance Portfolio Strength
Boston Scientific continued to fortify its leadership through key clinical trials and peer-reviewed publications, reflecting its commitment to data-driven innovation:
- Initiated ELEVATE-PF, a clinical trial assessing the FARAFLEX™ Mapping and Pulsed Field Ablation Catheter for persistent atrial fibrillation (AF).
- Launched OPTION-A in Asia-Pacific, evaluating the FARAPULSE™ PFA System used alongside the WATCHMAN™ Left Atrial Appendage Closure Device in a combined procedure.
- Showcased pivotal data from the SINGLE SHOT CHAMPION trial in The New England Journal of Medicine, where FARAPULSE™ PFA outperformed the Arctic Front Advance™ cryoablation catheter for paroxysmal AF.
- Highlighted results from the VITALYST Early Feasibility Study, revealing positive early outcomes using the VITALYST™ Temporary Circulatory Support System during high-risk coronary interventions.
Real-World Evidence and Acquisitions Strengthen Market Position
Beyond clinical development, Boston Scientific is leveraging real-world data to validate the long-term impact of its solutions. A study published in JAMA Network Open revealed that patients treated with SpaceOAR™ Hydrogel experienced a 25% lower risk of bowel disorders and a 46% reduction in invasive procedures post-radiation therapy for prostate cancer.
Strategic acquisitions further bolstered the company’s innovation pipeline:
- Acquired Bolt Medical, Inc., enhancing its capabilities in laser-based intravascular lithotripsy.
- Entered a definitive agreement to acquire SoniVie Ltd., developers of the TIVUS™ Intravascular Ultrasound System, an investigational device for treating hypertension through nerve denervation techniques.
Positioned for Sustained B2B Impact
Boston Scientific’s Q1 performance demonstrates the efficacy of its integrated B2B strategy, aligning operational excellence, innovation, and M&A execution. Its trajectory positions the company as a forward-looking leader in the medical technology space, ready to meet growing clinical demands with scalable, proven solutions.
Learn more at www.bostonscientific.com.